Weill Cornell Medicine company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

weill.cornell.edu

Founded Year

2016

Stage

Grant | Alive

Total Raised

$1.27M

Last Raised

$1.27M | 6 mos ago

About Weill Cornell Medicine

Weill Cornell Medicine is Cornell University's medical school located in New York City.

Weill Cornell Medicine Headquarter Location

1300 York Avenue

New York, New York, 10065,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Weill Cornell Medicine

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Weill Cornell Medicine is included in 1 Expert Collection, including Conference Exhibitors.

C

Conference Exhibitors

5,302 items

Weill Cornell Medicine Patents

Weill Cornell Medicine has filed 3 patents.

The 3 most popular patent topics include:

  • Acute myeloid leukemia
  • Nanomaterials
  • Nanoparticles
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/11/2019

Nanoparticles, Nanomaterials, Nanotechnology, Acute myeloid leukemia, Transcription factors

Application

Application Date

9/11/2019

Grant Date

Title

Related Topics

Nanoparticles, Nanomaterials, Nanotechnology, Acute myeloid leukemia, Transcription factors

Status

Application

Latest Weill Cornell Medicine News

Benefits of PSA prostate cancer screening found to be more favorable than previous estimates, especially for blacks

May 15, 2022

Benefits of PSA prostate cancer screening found to be more favorable than previous estimates, especially for blacks New research led by investigators from Weill Cornell Medicine, Fred Hutchinson Cancer Center, University Hospitals Cleveland and Case Western Reserve University found that prostate cancer screening with the prostate specific antigen (PSA) blood test has remarkably favorable tradeoffs. This is particularly true for Black men, the investigators found, who disproportionately bear the burden of prostate cancer mortality and morbidity, and who are underrepresented in clinical trials. Using epidemiologic data spanning a greater time period than previous estimates, the investigators produced new calculations of the number of men who were diagnosed and treated as a consequence of PSA screening as compared to the number of cancer deaths avoided. Their findings were published May 15 in NEJM Evidence. Previous calculations over a decade ago estimated that, at best, one death was prevented for every 23 men diagnosed with prostate cancer as a consequence of screening. This suggested that too many men were experiencing the negative effects of a prostate cancer diagnosis as compared to those who benefit to recommend use of the screening test. For their calculations, lead author Dr. Spyridon Basourakos, a resident in urology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, and colleagues improved on the previous estimates of overdiagnoses and overtreatment. Namely, they included 11 more years of data than prior estimates; calculated estimates for men of all races and Black men; and used complementary approaches to estimating overdiagnosis. Under conservative assumptions about screening’s benefits, the investigators estimated that for men of all races one death was prevented for every 11 to 14 men diagnosed with prostate cancer and every 7 to 11 men treated for the disease. For Black men screening resulted in one death prevented for every 8 to 12 men diagnosed, and every 5 to 9 men treated. For more optimistic assumptions about screening, these tradeoffs were even more favorable, with numbers needed to treat in the low single digits for Black men. The new analysis supports PSA screening, particularly for Black men and others at high risk, and highlight the need to revise clinical guidelines to accurately reflect the value of screening, the authors wrote. Lead author: Dr. Spyridon Basourakos, Weill Cornell Medicine Corresponding author: Dr. Jonathan Shoag, Case Western Reserve University, Weill Cornell Medicine Journal

Weill Cornell Medicine Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Weill Cornell Medicine Rank

  • When was Weill Cornell Medicine founded?

    Weill Cornell Medicine was founded in 2016.

  • Where is Weill Cornell Medicine's headquarters?

    Weill Cornell Medicine's headquarters is located at 1300 York Avenue, New York.

  • What is Weill Cornell Medicine's latest funding round?

    Weill Cornell Medicine's latest funding round is Grant.

  • How much did Weill Cornell Medicine raise?

    Weill Cornell Medicine raised a total of $1.27M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.